Mark Ward
Mark Ward is Operations Director at Star. To find out more about Star’s innovative outsourcing and resourcing solutions, please email outsourcing@starmedical.co.uk or resourcing@starmedical.co.uk. If you’re on the hunt for a new role, or just curious what’s out there, email your CV to candidates@starmedical.co.uk, or call 01225 336 335 to speak to a member of our team.
Latest articles
Electronic prescribing to help hospitals tackle medication errors
Patientrack's parent company has entered into a reseller agreement with healthcare software provider Better by Marand to help hospitals tackle medication errors. Patientrack provides...
Lack of public awareness in choice of hospitals when accessing NHS treatment
A new poll by Populus has identified a lack of public awareness in choice of hospitals when accessing NHS treatment. Populus interviewed 6116 adults online...
Seqirus to make entire influenza vaccine production process cell-based
Influenza vaccine manufacturer Seqirus is to manufacture its cell-based influenza vaccine (FLUCELVAX® TETRA) using cell-based Candidate Vaccine Viruses (CVVs) for all four strains recommended...
Popular articles
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Seqirus to make entire influenza vaccine production process cell-based
Influenza vaccine manufacturer Seqirus is to manufacture its cell-based influenza vaccine (FLUCELVAX® TETRA) using cell-based Candidate Vaccine Viruses (CVVs) for all four strains recommended...
Tegsedi™▼ to be available on the NHS for hATTR amyloidosis
NICE issues positive recommendation for inotersen to treat adult patients with stage 1 or stage 2 polyneuropathy with hATTR amyloidosis. Akcea Therapeutics UK Ltd., has...
NICE publishes final recommendation for ILUMETRI ®▼
NICE has published final recommendation for ILUMETRI ®▼ (Tildrakizumab), as a cost-effective option for adults with moderate-to-severe plaque psoriasis. The National Institute for Health and Care...
Novartis announce FDA Priority Review of brolucizumab for wet AMD
Novartis has recieved FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD. Novartis has announced that the US Food and...